This assessment addresses two subpopulations of interest:
1) adult obese patients (grade III obesity/BMI ≥40 or grade II obesity/BMI 35.0–39.9 with comorbidities)
2) patients with Type 2 DM and obesity ≥ grade I.
The DJBS is a 60 cm long impermeable sleeve-like device (fluoropolymer), placed endo-scopically under general anaesthesia into the small intestine for up to 12 months. The device is removed endoscopically [Australian Government: Department of Health and Ageing 2010, ECRI Institute 2012, National Institute for Health and Clinical Excellence 2012].
The HTA Core Model for Rapid Relative Effectiveness was the main source for selecting relevant assessment elements. A systematic literature search (without restriction on publi-cation date) of bibliographic databases, in the Cochrane Library and in the database of the Centre for Reviews and Dissemination, complemented by a SCOPUS handsearch, was used for compiling the domains ‘Safety’ and ‘Clinical effectiveness’.